Mobile

A clinical trial investigating safety and efficacy of a long-acting factor VIII in children (age <12 years) with severe hemophila A

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-004434-42

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated patients with hemophilia A Expansion group (Part 2) To further evaluate safety of BAY 94-9027 for prophylaxis and treatment of bleeding in PTPs with hemophilia A below 6 years of age.

Critère d'inclusion

  • Severe hemophilia A (< 1% FVIII:C)

Liens